RxDoctor Payments DataLook up a doctor →

Paul Harmatz

Pediatric Gastroenterology · Oakland, CANPI 1255435301

Payments from drug & device makers

$8,109,568in general payments, 2019–2025

Across 656 payments — averaging $12,362 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biomarin Pharmaceutical Inc.$4.9M
  • Takeda Pharmaceuticals U.S.A., Inc.$1.8M
  • Eli Lilly$484K
  • Shire North American Group Inc$458K
  • Swedish Orphan Biovitrum AB$183K
  • Ultragenyx Pharmaceutical Inc.$120K
  • plus $179K from 7 others
$7,719in research payments, 2019–2025

Across 7 payments — averaging $1102.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Chiesi USA, Inc.$6K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biomarin Pharmaceutical Inc.394$4,898,265
Takeda Pharmaceuticals U.S.A., Inc.103$1,788,301
Eli Lilly4$483,556
Shire North American Group Inc20$457,732
Swedish Orphan Biovitrum AB105$182,853
Ultragenyx Pharmaceutical Inc.6$120,318
Amicus Therapeutics, Inc.4$96,299
QED Therapeutics, Inc.4$49,510
Chiesi USA, Inc.4$16,328
Sanofi9$14,546
NS Pharma, Inc.1$1,735
Sobi, Inc1$89
Intrabio Inc1$33

How this compares

$8,109,568 in reported general payments places this provider in the 95th percentile of 220 pediatric gastroenterology providers in California.

See all pediatric gastroenterology providers in California →

Other pediatric gastroenterology in Oakland

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →